Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Venus Remedies is currently trading at Rs. 165.95, up by 1.60 points or 0.97% from its previous closing of Rs. 164.35 on the BSE.
The scrip opened at Rs. 165.00 and has touched a high and low of Rs. 166.90 and Rs. 164.00 respectively. So far 1880 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 275.95 on 28-Jul-2011 and a 52 week low of Rs. 141.05 on 22-Dec-2011.
Last one week high and low of the scrip stood at Rs. 173.90 and Rs. 161.00 respectively. The current market cap of the company is Rs. 150.66 crore.
The promoters holding in the company stood at 30.42% while Institutions and Non-Institutions held 15.83% and 53.75% respectively.
Venus Remedies has received the ‘BioSpectrum Product of the Year 2012’ award for its novel research product ‘ACHNIL’ a once-a-day painkiller. The award was presented at a glittering BioSpectrum Asia Award function in Singapore on March 16, 2012.
The product, ACHNIL was chosen for this award for its uniqueness in addressing a critical health condition. This novel formulation based on NDDS (novel drug delivery system) technology is going to fill the gap of long standing demand for better pain management therapy. ACHNIL starts its action instantly by giving immediate relief from acute pain and is effective for the next 24 hours as against the conventional daily dose of three injections of diclofenac given every 8 hours.
Aceclofenac (ACHNIL) is a radical innovation of Venus Medicine Research Centre which is a non steroidal anti-inflammatory drug (NSAID) and is used to relieve acute as well as chronic inflammation in rheumatoid arthritis. Osteoarthritis, low back pain, ankylosing spondylitis pain, dental pain post traumatic pain, gynecological pain and oncology pain. Venus has already secured patents for ACHNIL from India and Europe, which are valid up to 2025. Now, the company is all set to further strengthen its market position in India and the major European economies Germany, UK, France, Spain, Sweden, Italy and Switzerland.
Besides this, the company is also working on Antimicrobial Resistance, which is emerging as a biggest threat to the mankind. It is one of the very few R&D-led in the world working on AMR.
BioSpectrum Asia, the leading publication on Life Sciences in Asia-Pacific, which has started this award function in the year 2009 as an effort to identify and recognize the companies that are contributing to the industry's growth.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1514.50 |
| Dr. Reddys Lab | 6065.10 |
| Cipla | 1557.70 |
| Zydus Lifesciences | 1104.00 |
| Lupin | 1599.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
